Neuroptix Corporation

News

Cognoptix News

May 11, 2015   "2015 World Medical Innovation Forum" cites "Early Diagnosis and Treatment of Alzheimer's Disease" as the top field where breakthroughs will be made
Feb 05 2015   Cognoptix CEO Paul Hartung Says Company is Preparing for a Pivotal Phase 3 Clinical Trial of SAPPHIRE Eye Scan Being Developed to Aid in the Early Detection of Alzheimer's Disease
Jan 15, 2015   Cognoptix CEO Paul Hartung tells angel investors: "Our focus is to change the course of Alzheimer's disease."
Dec 03, 2014   Cognoptix Expands Clinical Advisory Board
Oct 08, 2014   Cognoptix elects its President and CEO, Paul D. Hartung, as Chairman of the Board, and welcomes new director, Dr. Christine de los Reyes, Alopexx Enterprises
Sep 30, 2014   Cognoptix raises over $15 million to fund pivotal clinical trial and final product development of eye test designed to identify early-stage Alzheimer’s Disease
Apr 02, 2014   Cognoptix President and CEO Paul Hartung Tells Analysts: “Our Vision is to Change the Course of Alzheimer’s Disease by Enabling Early Diagnosis at the Point of Care.”
Feb 14, 2014   Cognoptix Eye Test Generates Robust Results in Clinical Study to Identify Alzheimer’s Disease
Dec 04, 2013   Cognoptix President and CEO Paul Hartung Named “Emerging Medical Technologies Innovator of the Month” by Life Science Intelligence®
Nov 15, 2013   Cognoptix Eye Test Shows Impressive Results in Clinical Study to Identify Alzheimer’s Disease: 85% Sensitivity and 95% Specificity
Sep 30 2013   Clinical investigators comment on their study of Cognoptix eye test designed to identify Alzheimer’s disease that showed strong results: 85% sensitivity and 95% specificity
Sep 23 2013   Cognoptix eye test designed to identify Alzheimer’s disease shows strong results: 85% sensitivity and 95% specificity
Jul 15 2013   Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes
May 22 2013   Cognoptix Test Identifies Alzheimer’s Disease via Beta Amyloid Signature in the Eyes in Proof-of-Concept Clinical Trial
Apr 05 2013   Cognoptix expands its Clinical Advisory Board, adding Alzheimer's Disease-focused clinicians
Feb 28 2013   Cognoptix begins pre-pivotal clinical trial of its drug/device test designed to identify Alzheimer's disease via beta amyloid signature in the eyes
Jan 03 2013   Cognoptix Drug/Device Test Identifies Alzheimer's Disease via Beta Amyloid Signature in the Eyes in a 10-Subject Proof-of-Concept Clinical Trial
Dec 04 2012   Cognoptix Exclusively Licenses Alzheimer's-Detection Technology from the University of California at San Diego: Color-Coded Markers of Beta Amyloid That Empower Doctors to Diagnose Alzheimer's and Other Neural Diseases Through the Eyes
Oct 25 2012   Cognoptix CEO Paul Hartung to Speak at Biotech Showcase
Oct 20 2012   Cognoptix Announces Addition of Rajan Jethwa to Board of Directors
Oct 11 2012   Neuroptix Changes Its Name to Cognoptix
Jan 10 2011   Neuroptix Closes C Round Financing
Nov 04 2009   Neuroptix Corp. Announces Addition of Werner Schaefer to Board of Directors
Dec 15 2008   Neuroptix Corp. Names Gerald D. Cagle, Ph.D., as Chief Operating Officer
Oct 22 2008   Neuroptix Raises Successful B Round
Jan 28 2008   Neuroptix Corp. Announces Addition of Michael Henry and Stephen DiPalma to Board
Jul 16 2007   Neuroptix Announces $1 Million Milestone Payment in Collaboration with Merck & Co., Inc., for Early Detection and Monitoring of Alzheimer’s Disease Process
Apr 09 2007   Neuroptix Opens New Corporate Headquarters in Acton
Jan 18 2007   Neuroptix Expands Executive Team, Adds Evan Sherr as Vice President, Product Management, and Vincent Valvo as Vice President, Engineering and Product Development
Jan 18 2007   Neuroptix Announces Successful $1.6 Million Series A Funding Round
Dec 04 2006   Merck and Neuroptix Collaborate on Early Alzheimer’s Diagnostics Using Laser Eye Scanning
Sep 13 2006   Neuroptix Announces Breakthrough Preclinical Tests of QEL™ Platform for Non-Invasive Early Detection of Alzheimer’s
Jan 23 2006   Neuroptix Announces Successful Angel Investment Round Led by Launchpad Venture Group
Mar 08 2004   Neuroptix Announces Availability of Preclinical Research Instrument
Dec 15 2003   Neuroptix Announces Clinical Trial Agreement
Apr 12 2003   Neuroptix Announces Publication of Key Data in Peer Reviewed Lancet Article